XORTX Therapeutics Inc.
corporate_fare Company Profile
XORTX Therapeutics Inc. (NASDAQ:XRTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for XRTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-14, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for XRTX spans 6-K, 424B4, 20-F.
Recent high-impact activity:
- XORTX Q3 Interim Report: Going-Concern Warning, $318,846 Cash, Material Weakness Persists
- XORTX Adds Health Canada CTA Filing to Gout Program, Accelerating Global Regulatory Push
- XORTX Sets Q4 2026 FDA IND Submission for Gout Drug XORLO™, Targets NDA in About a Year
- XORTX Targets Q4 FDA Filing for Gout Drug, Sees $700M Market
- XORTX Re-Engages IR Agency with $2.5M Non-Refundable Fee After Delisting
Financial Snapshot
Short Interest & Short Volume
2.10 days to coverFINRA reported short interest of 122,511 shares in XRTX as of the October 30, 2026 settlement, a 48.3% decrease from the prior period — about 2.1 days to cover at its recent average daily volume. On November 20, 2026, 43.5% of XRTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
XRTX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.